About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
2019
15
Dec 2020
19:18 E.S.T.
Cellectis Announces Withdrawal of Follow-On Offering
Read more
14
Dec 2020
15:48 E.S.T.
Cellectis Announces Launch of Follow-On Offering
Read more
05
Dec 2020
17:00 E.S.T.
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
Read more
17
Nov 2020
18:58 E.S.T.
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma
Read more
16
Nov 2020
16:30 E.S.T.
Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer
Read more
05
Nov 2020
16:30 E.S.T.
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020
Read more
1
2
3
Next